Published today Nature Biotechnology: @CarlHJune and I reveal how CAR T cells are finally tackling solid tumors! Penn Postdoctoral Association Penn Medicine MD nature.com/articles/s4158…

NEW! Beyond the blood: expanding CAR T cell therapy to solid tumors Nature Biotechnology Ugur Uslu Carl June nature.com/articles/s4158…

CAR T cell #immunotherapy in autoimmune disease- the origin story and current status Science Magazine science.org/content/articl…

"I'm convinced CAR T cells could not have been made anywhere else," says Carl June. Hear how Penn's unique culture of collaboration helped progress the development of #CARTcell research beyond cancer into infectious diseases and beyond.

We are thrilled to share the 2024 class of Representation in SciencE (RISE) Scholars, a group of seven exceptional researchers selected through our Diversity, Equity, Inclusion and Belonging (DEIB) Program. Read our latest blog: parkerici.org/the-latest/par…

Grateful to be named a 2024 RISE Scholar by Parker Institute for Cancer Immunotherapy, alongside this incredible group of researchers driving advancements in cancer immunotherapy. Honored to be part of this effort toward a future where all cancers are curable!

Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research The Parker Institute for Cancer Immunotherapy (Parker Institute for Cancer Immunotherapy) announces its inaugural RISE Scholars, funding seven researchers with $75,000 each to tackle critical challenges in immunotherapy.

Congrats Sofía Castelli Penn Medicine on being named a Representation in SciencE (RISE) Scholar award recipient Parker Institute for Cancer Immunotherapy Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research parkerici.org/the-latest/par…

Penn Medicine’s clinical research teams are hidden heroes of #CARTcelltherapy. From taking care of patients at the bedside to collecting and analyzing data, their work is vital to moving innovative research forward. spr.ly/6015aR87Z

The 2024 VinFuture Prize Special Prize for Innovators with Outstanding Achievements in Emerging Fields was awarded last month to Zelig Eshhar, Penn Medicine - Abramson Cancer Center's Carl June, and Michel Sadelain for development of #CARTCellTherapy for cancer and other diseases. spr.ly/6017aS2N7

IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing anti-tumor efficacy biorxiv.org/content/10.110… #biorxiv_immuno

IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing anti-tumor efficacy doi.org/10.1101/2025.0… Carl June Sofía Castelli

Excited to share my PhD thesis work with @CarlHJune now out as a preprint on bioRxiv! We show that engineering IL-9 signaling enhances CAR T cell antitumor efficacy by steering them toward potent memory and effector states. biorxiv.org/content/10.110…

Crystal Mackall and Carl June discussed groundbreaking strategies to enhance CAR T-cell therapies, pushing the boundaries for solid cancer treatment on day 3 of #AACRIO25. Learn more on the #AACRBlog: brnw.ch/21wR0gf Parker Institute for Cancer Immunotherapy Penn Medicine

CAR T-cell therapy has transformed treatment for 35K+ patients, with a well-established safety profile. New in The Lancet: Carl June, Director of the PICI Center at Penn Medicine, Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 & Daniel Baker explore latest data and what’s next in the field. thelancet.com/journals/lance…

CAR T-cell therapy isn’t just a breakthrough—it’s a lifeline. A new PICI-supported review in Molecular Therapy by Carl June, Director of the PICI Center at Penn Medicine, and team traces the decades of research that made engineered immune cells a powerful cancer treatment.

Penn researchers found that next-generation IL18-armored #CARTCellTherapy shows promise for patients whose #lymphoma resisted multiple other cancer treatments, including commercial CAR T cell therapies. Carl June NEJM AACR #NCRM #UnitedByCancerResearch spr.ly/6019NpiON

Congratulations to our own Drs. June and Levine!

A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients with B-cell lymphoma who had exhausted other treatment options ft. Carl June (Penn Path & Lab Medicine) & Jakub Svoboda (Penn Medicine - Abramson Cancer Center) Institute for Immunology and Immune Health (I3H) tinyurl.com/3ejw9334

🚨Coming soon! Multiplex engineering using microRNA-mediated gene silencing in CAR T cells. In a single lentiviral vector- multiplex silencing & expression of a CAR, better expansion & viability than gene editing by electroporation Penn Medicine antionbio.com